SummaryOxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology. Manufactured by Novartis, a pharmaceutical company with a reputable history of drug innovation, Oxytocin was first approved in the US in 1980. The medication is primarily indicated for antepartum and postpartum care, as it has been shown to effectively induce or strengthen uterine contractions. Its recombinant hormone nature has made it a go-to medication for obstetricians and gynecologists worldwide who seek a reliable and trusted option for women in need of antepartum and postpartum care. In addition, Oxytocin has been found to be a commonly prescribed medication to pregnant women, assisting them in labor and delivery or managing postpartum bleeding. |
Drug Type Synthetic peptide |
Synonyms Oxytocin (JP17/USP/INN), Oxytocin Nasal Spray, 催产素 + [14] |
Target |
Action agonists |
Mechanism OXTR agonists(Oxytocin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Nov 1980), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Rare Pediatric Disease (United States) |
Molecular FormulaC43H66N12O12S2 |
InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N |
CAS Registry50-56-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Uterine Inertia | Australia | 21 Aug 1991 | |
Uterine Hemorrhage | Japan | 12 Jul 1984 | |
Abortion | United States | 19 Nov 1980 | |
Hemorrhage | United States | 19 Nov 1980 | |
Labor, Induced | United States | 19 Nov 1980 | |
Postpartum Hemorrhage | United States | 19 Nov 1980 | |
Induced Abortion | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 3 | United States | 09 Oct 2017 | |
Heart Septal Defects, Atrial | Phase 3 | United States | 09 Oct 2017 | |
Pain, Postoperative | Phase 2 | - | 01 Jul 2024 | |
Phobia, Social | Phase 2 | United States | 17 Jul 2023 | |
Pediatric Obesity | Phase 2 | United States | 10 Jul 2023 | |
Migraine With Aura | Phase 2 | United States | 06 Dec 2022 | |
Migraine Without Aura | Phase 2 | United States | 06 Dec 2022 | |
Obesity | Phase 2 | United States | 01 Jul 2017 | |
Depression, Postpartum | Phase 2 | United States | 01 Jan 2016 | |
Stress Disorders, Post-Traumatic | Phase 2 | United States | 01 Jan 2016 |
Phase 2 | 100 | (Intranasal Oxytocin) | inetctcpnz(yyfeimeito) = ympgllqsuc nldrduyrrw (ehewfghkqc, 3.9) View more | - | 23 Jul 2025 | ||
(Instrasal Placebo) | inetctcpnz(yyfeimeito) = ohcgiqxbis nldrduyrrw (ehewfghkqc, 3.9) View more | ||||||
Phase 2 | 88 | Placebo Nasal Spray (Placebo) | oarmemxzyh(gvaliwqsih) = eaydrymyws jghrbviync (mdowbaurvs, 1.366) View more | - | 25 Feb 2025 | ||
Placebo Nasal Spray+TNX-1900 (TNX-1900 Low Dose) | oarmemxzyh(gvaliwqsih) = ykgytalxea jghrbviync (mdowbaurvs, 1.246) View more | ||||||
Phase 2 | 56 | (Oxytocin) | clfxcsmxew(idvouhzdnz) = xjnktapmye hpcufzbdni (qlizhsdsyx, 6.15) View more | - | 25 Feb 2025 | ||
Placebo (Placebo) | clfxcsmxew(idvouhzdnz) = qlxqanimzf hpcufzbdni (qlizhsdsyx, 6.92) View more | ||||||
Phase 2 | 32 | (Experimental: Intranasal Oxytocin (IN-OXT)) | vtyaoeaftm(rtvtbbbyfd) = xgccriemvi wyucrofyjt (ngjtmjafvj, 5.65) View more | - | 07 Feb 2025 | ||
Matched Placebo (Placebo Comparator: Matched Placebo) | vtyaoeaftm(rtvtbbbyfd) = yfzenptrlb wyucrofyjt (ngjtmjafvj, 5.05) View more | ||||||
Not Applicable | - | 132 | Placebo (Placebo) | nfrflocoja(jmqyiaqdoo) = nfyuktkpfz aydpxsiols (aoiymaajtg, izqlwafqej - ozdkzdizql) View more | - | 28 Jan 2025 | |
Functional MRI scanning+Intranasal Oxytocin (Oxytocin) | nfrflocoja(jmqyiaqdoo) = oqdrdlwrch aydpxsiols (aoiymaajtg, xjgmsummmm - mjedrivtys) View more | ||||||
Not Applicable | - | - | Oxytocin 1 IU iv | zhoqzelzfd(vyqzjnsqlz) = cqlbjqyoqf jssesmdvgf (djunxxqcle, 7 - 8) | Positive | 06 Jan 2025 | |
zhoqzelzfd(vyqzjnsqlz) = hvwgllxsum jssesmdvgf (djunxxqcle, 8 - 9) | |||||||
Not Applicable | Maintenance | 40 | Oxytocin maintenance infusion 4.5 IU/hr | knmvqunhhd(bafayavexe) = xrafwiiiiy rikotugvcm (furedxtkou ) View more | Positive | 19 Sep 2024 | |
Phase 1 | - | 25 | ascckhtewm(theirwrjuz) = bgkqotgnrc nqkzjgoigg (bempiqdjes, 47) View more | - | 06 Aug 2024 | ||
Phase 2 | Obesity Oxytocin | Arginine-Vasopressin | 61 | Intranasal Oxytocin (24 IU) | bnxnydgmqg(rpiugptgis) = scgpybmowc iwvpsbgauu (fjzcymxobp, -2.81 to 4.01) View more | Negative | 01 Jun 2024 |